Skip to main content

Enliven Therapeutics, Inc.

ELVN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001672619

In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 214 institutions reported holding it in 13F filings for Q2 2026, worth $4.06B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Enliven Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
8 filings
4 insiders, $11.8M in total
Insiders trading
4
Net value
−$11.8M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Enliven Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Enliven Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Hohl BenjaminCHIEF FINANCIAL OFFICER38,000Sep 21, 20268
Collins Helen LouiseCHIEF MEDICAL OFFICER25,000Sep 21, 202611
Derynck Mika KDirector0Aug 6, 20262
Kunkel Lori AnneDirector41,884Jul 8, 20264
OrbiMed Advisors LLC10% Owner6,555,102IndirectJun 24, 20262
OrbiMed Capital GP VII LLC10% Owner6,555,102IndirectJun 24, 20262
OrbiMed Genesis GP LLC10% Owner6,555,102IndirectJun 24, 20262
Heyman Richard A.Director22,647IndirectFeb 19, 20264
Garland J. ScottDirector–Feb 17, 20262
Gupta RishiDirector7,663,349IndirectFeb 17, 20261
Bauer JakeDirector87,372Feb 17, 20261
Ballal Rahul D.Director22,341Feb 17, 20261
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER18,750Feb 17, 20268
Patel AnishCHIEF OPERATING OFFICER20,000Feb 17, 20265
Fair Richard A.PRESIDENT AND CEO–Dec 12, 20251
Kintz SamuelPRESIDENT AND CEO890,392IndirectNov 19, 20253
Phillips Andrew JohnDirector–Feb 10, 20250
Schwab Andrew J.10% Owner635,341IndirectFeb 16, 20240
Parmar Kush10% Owner635,341IndirectFeb 16, 20240
5AM Opportunities I, L.P.10% Owner635,341IndirectFeb 16, 20240
5AM Ventures VI, L.P.10% Owner635,341IndirectFeb 16, 20240
5AM Opportunities I (GP), LLC10% Owner635,341IndirectFeb 16, 20240
5AM Partners VI, LLC10% Owner635,341IndirectFeb 16, 20240
RA Capital Healthcare Fund LPOther: Former 10% owner2,122,465IndirectFeb 27, 20230
Ra Capital Management, L.P.Other: Former 10% owner2,122,465IndirectFeb 27, 20230
Kolchinsky PeterOther: Former 10% owner2,122,465IndirectFeb 27, 20230
Shah Rajeev M.Other: Former 10% owner2,122,465IndirectFeb 27, 20230
Commodore Capital LP10% Owner1,448,640IndirectFeb 27, 20230
Gray MichaelCFO & COO27,610Feb 22, 20230
Leonard Braden Michael10% Owner1,767,774IndirectJan 5, 20230
Goldfischer CarlDirector–Jun 3, 20220
Mott David MDirector229,224Jun 3, 20220
Bonita David PDirector, 10% Owner4,199,068IndirectJun 3, 20220
Dalton BarbaraDirector–Jun 3, 20220
Conner Edward R.Director–Jun 3, 20220
Chin MarkDirector2,344,072IndirectJun 3, 20220
Williams Laura ADirector–Jun 3, 20220
Kerins Patrick J10% Owner2,611,050Apr 7, 20220
Sandell Scott D10% Owner2,611,050Apr 7, 20220
Baskett Forest10% Owner2,611,050Apr 7, 20220
New Enterprise Associates 14, L.P.10% Owner2,611,050Apr 7, 20220
NEA Partners 14, L.P.10% Owner2,611,050Apr 7, 20220
Nea 14 GP, Ltd10% Owner2,611,050Apr 7, 20220
Sonsini Peter W.10% Owner2,611,050Apr 7, 20220
Florence Anthony A. Jr.10% Owner2,611,050Apr 7, 20220
Attie KennethSVP, CMO34,100Feb 1, 20220
OrbiMed Capital LLCDirector, 10% Owner1,666,666IndirectJul 16, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 3, 2024 (view filing)Jul 12 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.0K$22.89−$274.7K−1.1%1.11M after10b5-1
Jul 16, 2024 (view filing)Jul 124 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−3.00K$25.07−$75.2K−100.0%0 after10b5-1
Jul 16, 2024 (view filing)Jul 12-164 daysPatel AnishCHIEF OPERATING OFFICERSSale−50.0K$25.06−$1.25M−12.7%344.0K after3 lots10b5-1
Jul 17, 2024 (view filing)Jul 152 daysHeyman Richard A.DirectorSSale−1.27K$24.80−$31.5K−0.9%133.3K after10b5-1
Jul 29, 2024 (view filing)Jul 254 daysKintz SamuelPRESIDENT AND CEOSSale−12.0K$24.92−$299.1K−1.1%1.06M after3 lots10b5-1
Jul 31, 2024 (view filing)Jul 292 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−5.25K$26.68−$140.1K−100.0%0 after2 lots10b5-1
Jul 31, 2024 (view filing)Jul 292 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.0K$26.70−$320.4K−1.1%1.09M after2 lots10b5-1
Aug 2, 2024 (view filing)Jul 312 daysHeyman Richard A.DirectorSSale−1.70K$27.51−$46.8K−1.3%131.6K after10b5-1
Aug 2, 2024 (view filing)Jul 312 daysHeyman Richard A.DirectorSSale−649$27.50−$17.8K−2.3%27.9K after10b5-1
Aug 2, 2024 (view filing)Jul 312 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−991$27.53−$27.3K−100.0%0 after10b5-1
Aug 2, 2024 (view filing)Jul 312 daysKintz SamuelPRESIDENT AND CEOSSale−2.27K$27.56−$62.6K−0.2%1.06M after10b5-1
Aug 2, 2024 (view filing)Jul 312 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−3.10K$27.56−$85.4K−0.3%1.09M after10b5-1
Aug 19, 2024 (view filing)Aug 154 daysHeyman Richard A.DirectorSSale−1.27K$23.25−$29.5K−1.0%130.4K after2 lots10b5-1
Aug 28, 2024 (view filing)Aug 262 daysKintz SamuelPRESIDENT AND CEOSSale−12.0K$22.89−$274.7K−1.1%1.05M after10b5-1
Aug 29, 2024 (view filing)Aug 272 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−4.25K$22.54−$95.8K−100.0%0 after10b5-1
Sep 3, 2024 (view filing)Aug 295 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.0K$22.48−$269.8K−1.1%1.08M after2 lots10b5-1
Sep 18, 2024 (view filing)Sep 162 daysHeyman Richard A.DirectorSSale−1.27K$22.41−$28.5K−1.0%129.1K after10b5-1
Oct 1, 2024 (view filing)Sep 27-304 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−6.25K$24.61−$153.8K−100.0%0 after2 lots10b5-1
Oct 3, 2024 (view filing)Oct 12 daysHeyman Richard A.DirectorSSale−518$27.54−$14.3K−0.4%128.6K after10b5-1
Oct 3, 2024 (view filing)Oct 12 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−521$27.54−$14.3K−100.0%0 after10b5-1
Oct 3, 2024 (view filing)Oct 12 daysKintz SamuelPRESIDENT AND CEOSSale−526$27.54−$14.5K−0.1%1.05M after10b5-1
Oct 3, 2024 (view filing)Oct 12 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−527$27.54−$14.5K0.0%1.08M after10b5-1
Oct 8, 2024 (view filing)Oct 44 daysHeyman Richard A.DirectorSSale−2.83K$27.51−$77.7K−2.2%125.8K after10b5-1
Oct 8, 2024 (view filing)Oct 4-74 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−11.5K$27.51−$316.0K−100.0%0 after2 lots10b5-1
Oct 8, 2024 (view filing)Oct 4-74 daysKintz SamuelPRESIDENT AND CEOSSale−14.9K$27.51−$410.9K−1.4%1.03M after2 lots10b5-1
Oct 8, 2024 (view filing)Oct 4-74 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−10.2K$27.54−$281.7K−0.9%1.07M after2 lots10b5-1
Oct 10, 2024 (view filing)Oct 82 daysBallal Rahul D.DirectorSSale−10.4K$28.17−$293.5K−31.8%22.3K after10b5-1
Oct 10, 2024 (view filing)Oct 8-92 daysKintz SamuelPRESIDENT AND CEOSSale−30.0K$28.06−$841.2K−2.9%1.00M after4 lots10b5-1
Oct 10, 2024 (view filing)Oct 8-92 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−51.1K$28.11−$1.44M−4.8%1.02M after4 lots10b5-1
Oct 17, 2024 (view filing)Oct 152 daysHeyman Richard A.DirectorSSale−1.27K$27.67−$35.1K−1.0%124.5K after10b5-1
Oct 22, 2024 (view filing)Oct 184 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−816$30.00−$24.5K−100.0%0 after10b5-1
Oct 22, 2024 (view filing)Oct 184 daysHeyman Richard A.DirectorSSale−817$30.00−$24.5K−0.7%123.7K after10b5-1
Oct 22, 2024 (view filing)Oct 184 daysHeyman Richard A.DirectorSSale−753$30.00−$22.6K−2.7%27.2K after10b5-1
Oct 22, 2024 (view filing)Oct 184 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−814$30.00−$24.4K−100.0%0 after10b5-1
Oct 22, 2024 (view filing)Oct 184 daysKintz SamuelPRESIDENT AND CEOSSale−924$30.00−$27.7K−0.1%1.00M after10b5-1
Oct 22, 2024 (view filing)Oct 184 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−847$30.00−$25.4K−0.1%1.02M after10b5-1
Oct 22, 2024 (view filing)Oct 184 daysPatel AnishCHIEF OPERATING OFFICERSSale−716$30.00−$21.5K−0.2%343.3K after10b5-1
Oct 30, 2024 (view filing)Oct 282 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−6.25K$28.55−$178.5K−100.0%0 after2 lots10b5-1
Dec 2, 2024 (view filing)Nov 275 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−5.25K$24.89−$130.7K−100.0%0 after2 lots10b5-1
Dec 31, 2024 (view filing)Dec 27-304 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−4.25K$22.23−$94.5K−100.0%0 after2 lots10b5-1
Jan 7, 2025 (view filing)Jan 34 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−1.00K$25.04−$25.0K−7.1%13.0K after10b5-1
Jan 10, 2025 (view filing)Jan 73 daysPatel AnishCHIEF OPERATING OFFICERSSale−21.7K$24.18−$524.6K−100.0%0 after2 lots10b5-1
Jan 10, 2025 (view filing)Jan 73 daysPatel AnishCHIEF OPERATING OFFICERSSale−6.67K$24.18−$161.2K−1.9%336.6K after2 lots10b5-1
Jan 29, 2025 (view filing)Jan 272 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−3.25K$21.59−$70.2K−20.0%13.0K after10b5-1
Feb 7, 2025 (view filing)Feb 52 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−1.00K$22.52−$22.5K−7.1%13.0K after10b5-1
Feb 10, 2025 (view filing)Feb 73 daysPatel AnishCHIEF OPERATING OFFICERSSale−6.67K$21.93−$146.2K−2.0%330.0K after
Mar 3, 2025 (view filing)Feb 274 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−3.25K$20.41−$66.3K−20.0%13.0K after10b5-1
Mar 11, 2025 (view filing)Mar 74 daysPatel AnishCHIEF OPERATING OFFICERSSale−6.67K$21.44−$142.9K−2.0%323.3K after10b5-1
Mar 19, 2025 (view filing)Mar 172 daysKintz SamuelPRESIDENT AND CEOSSale−12.5K$20.83−$260.4K−1.2%990.4K after10b5-1
Mar 21, 2025 (view filing)Mar 192 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.5K$20.61−$257.6K−1.2%1.00M after10b5-1